Present status of chymopapain and chemonucleolysis

Area of Science:

• Biomedical research
• Pharmacology
• Surgical techniques

Background:

• Chymopapain, an enzyme derived from papaya latex, was historically used for Chemonucleolysis to treat herniated intervertebral discs.
• The FDA curtailed its use in the United States due to safety concerns and adverse events.
• Recent advancements in clinical and basic research necessitate a re-evaluation of Chymopapain's therapeutic potential.

Purpose of the Study:

• To objectively analyze recent data and events concerning Chymopapain and Chemonucleolysis.
• To review the clinical and basic research supporting the efficacy and safety of Chymopapain.
• To examine the factors contributing to the FDA's previous decision to restrict Chymopapain's use.

Main Methods:

• Comprehensive literature review of published studies on Chymopapain and Chemonucleolysis.
• Analysis of clinical trial data and basic science research findings.
• Examination of historical FDA regulatory actions and their rationale.

Main Results:

• Recent research indicates improved understanding and management of potential adverse events associated with Chymopapain.
• Clinical data suggests Chymopapain remains a viable option for specific patient populations with herniated discs.
• The circumstances leading to the FDA curtailment are better understood, with potential mitigation strategies identified.

Conclusions:

• The current body of evidence supports the reintroduction of Chymopapain for investigational use.
• Further research under controlled investigational protocols is warranted to fully assess its risk-benefit profile.
• Revisiting Chymopapain's therapeutic role could offer an alternative treatment for patients unresponsive to conservative management.